Bio-Rad is a "picks and shovels" company in the life sciences industry, but lacks standout growth, margins, or returns, and that has been largely true for more than two decades. Recent trends in the ...

I rate Bio-Rad (BIO) with a buy rating. I start by mentioning that the low growth perspective is the negative aspect. For 2025, the company expects a 0.25% growth rate for its revenues, which might ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2025 Earnings Call Transcript February 12, 2026 Bio-Rad Laboratories, Inc. misses on earnings expectations. Reported EPS is $2.51 EPS, expectations were $2.57.

G2 Bio Companies has launched with $200 million in financing from Temasek to develop gene therapy candidates out of the University of Pennsylvania. The company is led by Penn gene therapy expert James ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced its intent to separate its severe genetic disease and oncology businesses into differentiated and independent publicly ...

CAMBRIDGE, Mass. & CAMBRIDGE, England--(BUSINESS WIRE)--Transition Bio, Inc. (“Transition Bio” or the “Company”) was recently formed, funded, and launched with the focused objective to build the best ...

Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital Carlyle Group and SK Capital Partners increased their upfront offer to take over gene therapy maker bluebird bio , the ...

Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026 ...

Bluebird Bio, Inc. (NASDAQ:BLUE), on Friday, entered into a definitive agreement to be acquired by global investment firms Carlyle Group Inc. (NASDAQ:CG) and SK Capital Partners. The agreement, which ...